公开(公告)号：US20230384324A1

公开(公告)日：2023-11-30

申请号：US18250780

申请日：2021-11-11

申请人： Northwestern University

发明人： Lorenzo Gallon ,  Robert V. Gerbasi

IPC分类号： G01N33/68

CPC分类号： G01N33/6893 ,  G01N2333/70546 ,  G01N2800/347

摘要： A system and method for identifying and/or predicting damage or disease of a patient's kidney podocyte layer, wherein the system includes a test kit configured to analyze the plasma or urine of the patient; and identify the presence of focal adhesion complex proteins, or anti-bodies associated with the focal adhesion complex proteins, in the plasma or urine, wherein the focal adhesion complex proteins comprise Integrin, Talin, Filamin, Vinculin, or other focal adhesion complex proteins. Wherein the presence of the focal adhesion complex proteins indicates damage or disease to the patient's podocyte layer and the presence of the associated anti-bodies may be used to predict the likelihood of developing damage.

公开(公告)号：US11686734B2

公开(公告)日：2023-06-27

申请号：US16923043

申请日：2020-07-07

申请人： Biogen MA Inc.

发明人： Meena Subramanyam ,  Lakshimi Amaravadi ,  Eric Wakshull ,  Frances Lynn ,  Michael Panzara ,  Robin McDaid Barbour ,  Julie Elizabeth Taylor

IPC分类号： G01N33/68 ,  C07K16/28

CPC分类号： G01N33/6854 ,  C07K16/2839 ,  G01N33/686 ,  G01N2333/70546 ,  G01N2800/065 ,  G01N2800/102 ,  G01N2800/285 ,  G01N2800/52

摘要： The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. Aspects of the invention relate to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of a VLA4 binding antibody (e.g., natalizumab).

公开(公告)号：US11680948B2

公开(公告)日：2023-06-20

申请号：US16324878

申请日：2017-08-11

申请人： ABREOS BIOSCIENCES, INC.

发明人： Bradley T. Messmer ,  Dina Uzri ,  Jessie-Farah Fecteau

IPC分类号： G01N33/68

CPC分类号： G01N33/6854 ,  G01N2333/70546

摘要： Methods and assays for detecting natalizumab in a sample, natalizumab-peptide complexes in a sample, and point-of-care devices for detecting natalizumab in a sample are described herein.

公开(公告)号：US20180238866A1

公开(公告)日：2018-08-23

申请号：US15526573

申请日：2015-11-12

申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

发明人： Yoshikazu TAKADA ,  Yoko TAKADA ,  Masaaki FUJITA

IPC分类号： G01N33/543 ,  A61K38/17 ,  C07K14/705 ,  G01N33/533 ,  G01N33/52 ,  G01N33/58 ,  G01N33/53 ,  G01N33/566

CPC分类号： G01N33/54306 ,  A61K38/00 ,  A61K38/177 ,  C07K14/70546 ,  G01N33/52 ,  G01N33/5306 ,  G01N33/533 ,  G01N33/566 ,  G01N33/582 ,  G01N2333/70546 ,  G01N2333/92 ,  G01N2500/02

摘要： The present invention relates to the discovery that a secretory phospholipase A2 (sPLA2-IIA) plays an active role in mediating cellular signaling leading to an inflammatory response or cell proliferation by way of its specific binding with integrin β at site 2 of integrin β. More specifically, the invention provides a method for identifying inhibitors of inflammatory or proliferative signaling by screening for compounds that interrupt the specific binding of sPLA2 and integrin β at site 2. The invention also provides the novel use of a substance that suppresses the specific binding between sPLA2 and site 2 of integrinβ for the purpose of treating or preventing a condition involving an undesired inflammatory response or cell proliferation.

公开(公告)号：US20180045724A1

公开(公告)日：2018-02-15

申请号：US15674427

申请日：2017-08-10

申请人： VETICA LABS, INC.

发明人： Juan ESTRUCH ,  Genevieve HANSEN

IPC分类号： G01N33/564 ,  C07K14/705 ,  C07K14/47

CPC分类号： G01N33/564 ,  C07K14/4713 ,  C07K14/4718 ,  C07K14/4728 ,  C07K14/4737 ,  C07K14/70546 ,  C07K14/79 ,  C07K16/00 ,  C07K2319/21 ,  G01N2333/4727 ,  G01N2333/70546 ,  G01N2800/062 ,  G01N2800/065 ,  G01N2800/50 ,  G01N2800/7095

摘要： The present invention provides methods and systems to accurately detect and measure in a biological sample from a patient, endogenous antibodies, e.g., IgA, to inflammatory proteins, which antibodies are useful as diagnostic markers for inflammatory conditions, including bowel disease (IBD), in patients. Such methods and systems identify whether a sample from the patient is associated with an inflammatory condition, by using non-invasive means, thus conveniently providing information useful for guiding treatment decisions.

公开(公告)号：US09709575B2

公开(公告)日：2017-07-18

申请号：US14330619

申请日：2014-07-14

申请人： Biogen MA Inc.

发明人： Meena Subramanyam ,  Lakshmi Amaravadi ,  Eric Wakshull ,  Frances Lynn ,  Michael Panzara ,  Robin McDaid Barbour ,  Julie Elizabeth Taylor

IPC分类号： C07K16/28 ,  G01N33/68

CPC分类号： G01N33/6854 ,  C07K16/2839 ,  G01N33/686 ,  G01N2333/70546 ,  G01N2800/065 ,  G01N2800/102 ,  G01N2800/285 ,  G01N2800/52

摘要： The invention relates to methods and products for the identification of a clinically significant immune response in subjects treated with a therapeutic protein. A first aspect of the invention relates to methods and compositions for identifying a clinically significant immune response in patients treated with therapeutic amounts of VLA4 binding antibody (e.g., natalizumab). A second aspect of the invention concerns the chronological details of sample collection for determining the titer of antibodies against the therapeutic protein, e.g. the collection of at least two samples at two different time points. A third aspect of the invention relates to the selection of the critical threshold level, which corresponds to the antibody titer of untreated patients increased by the double of the standard deviation of this control antibody titer.

公开(公告)号：US20160280789A1

公开(公告)日：2016-09-29

申请号：US15033879

申请日：2014-11-10

申请人： CHILDREN'S HOSPITAL LOS ANGELES ,  FRED HUTCHINSON CANCER RESEARCH CENTER

发明人： Yong-mi Kim ,  Elizabeth Wayner

IPC分类号： C07K16/28 ,  A61K47/48 ,  A61K39/395 ,  A61K45/06

CPC分类号： C07K16/2839 ,  A61K39/39575 ,  A61K45/06 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/73 ,  C07K2317/76 ,  G01N33/57426 ,  G01N2333/70546

摘要： Described herein are methods for treating hematological malignancies and/or solid tumors in a subject using inhibitors of integrin alpha 6. In some embodiments, the inhibitors are monoclonal antibodies. The antibodies may be conjugated to additional therapeutic agents. The antibodies may be co-administered sequentially or simultaneously with additional therapeutic agents.

摘要翻译： 本文描述的是使用整联蛋白α6抑制剂治疗受试者的血液恶性肿瘤和/或实体瘤的方法。在一些实施方案中，抑制剂是单克隆抗体。 抗体可以与另外的治疗剂缀合。 抗体可以与其它治疗剂相继或同时共施用。

公开(公告)号：US20160238613A1

公开(公告)日：2016-08-18

申请号：US15025670

申请日：2014-09-26

申请人： X-BODY, INC.

发明人： Richard W. Wagner

IPC分类号： G01N33/68 ,  G01N21/78 ,  C07K16/28

CPC分类号： G01N33/6845 ,  C07K16/2821 ,  C07K16/2845 ,  C07K2317/21 ,  C07K2317/54 ,  C07K2317/565 ,  C07K2317/567 ,  G01N21/78 ,  G01N33/6854 ,  G01N2021/7773 ,  G01N2333/70525 ,  G01N2333/70546 ,  G01N2333/70553 ,  G01N2500/04 ,  G01N2500/10

摘要： The present invention provides methods for the identification of an antigen receptor (e.g., an antibody) that specifically binds to an antigen of interest. Generally, this involves contacting a plurality of antigen receptor-expressing cells with an antigen of interest; measuring the level of activated adhesion molecules on the surface of the antigen receptor-expressing cells; and, identifying from the plurality of antigen receptor-expressing cells an antigen receptor-expressing cell that exhibits an increased amount of activated adhesion molecules on the cell surface.

摘要翻译： 本发明提供了鉴定与感兴趣抗原特异性结合的抗原受体（例如抗体）的方法。 通常，这涉及使多个抗原受体表达细胞与感兴趣的抗原接触; 测量表达抗原受体的细胞上活化的粘附分子的水平; 并且从多个抗原受体表达细胞中鉴定表达细胞表面上活化的粘附分子数量增加的抗原受体表达细胞。

公开(公告)号：US20150307611A1

公开(公告)日：2015-10-29

申请号：US14675081

申请日：2015-03-31

申请人： GENENTECH, INC.

发明人： Mary Keir ,  Gaik Wei Tew

IPC分类号： C07K16/28 ,  G01N33/68 ,  C12Q1/68

CPC分类号： C07K16/2839 ,  C07K2317/24 ,  C12Q1/6883 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N33/6872 ,  G01N33/6893 ,  G01N2333/7051 ,  G01N2333/70546 ,  G01N2800/06 ,  G01N2800/065 ,  G01N2800/52

摘要： Biomarkers predictive of responsiveness to integrin beta7 antagonists, including anti-beta7 integrin subunit antibodies, and methods of using such biomarkers are provided. In addition, methods of treating gastrointestinal inflammatory disorders such as inflammatory bowel diseases including ulcerative colitis and Crohn's disease are provided. Also provided are methods of using such predictive biomarkers for the treatment of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.

摘要翻译： 提供了预测对整合素β7拮抗剂（包括抗β7整联蛋白亚单位抗体）的反应性的生物标志物和使用这些生物标志物的方法。 此外，提供了治疗胃肠道炎症性疾病如包括溃疡性结肠炎和克罗恩病的炎症性肠病的方法。 还提供了使用这种预测性生物标志物治疗包括溃疡性结肠炎和克罗恩病的炎症性肠病的方法。

公开(公告)号：US09073995B2

公开(公告)日：2015-07-07

申请号：US13814446

申请日：2011-08-12

申请人： Chong Li ,  Zusen Fan ,  Honglian Zhang ,  Zhonghua Dai ,  Haidong Tang ,  Jun Chen

发明人： Chong Li ,  Zusen Fan ,  Honglian Zhang ,  Zhonghua Dai ,  Haidong Tang ,  Jun Chen

IPC分类号： G01N33/53 ,  C07K16/00 ,  C07K16/28 ,  C07K14/705 ,  G01N33/574 ,  G01N33/68 ,  C12N15/113 ,  C12Q1/48 ,  C12Q1/02 ,  A61K47/48 ,  A61K51/10 ,  A61K45/06 ,  A61K39/395 ,  C07K16/30 ,  C12N9/10

CPC分类号： C07K16/2842 ,  A61K39/39558 ,  A61K45/06 ,  A61K47/48607 ,  A61K47/6861 ,  A61K51/1093 ,  C07K14/70546 ,  C07K14/7055 ,  C07K16/3038 ,  C12N9/1051 ,  C12N15/1137 ,  C12Q1/025 ,  C12Q1/48 ,  C12Y204/01041 ,  G01N33/57484 ,  G01N33/57488 ,  G01N33/6854 ,  G01N2333/70546 ,  G01N2440/38

摘要： Provided in the present invention are an aberrantly glycosylated integrin, AG-α3β1, and use thereof as a bladder cancer marker. Also provided in the present invention are a hybridoma cell generating an anti-AG-α3β1 monoclonal antibody, a monoclonal antibody BCMab1 secreted by the same, and use of BCMab1 in the preparation of a medicament for the treatment of bladder cancer. Also provided in the present invention is use of inhibitors of GAL3ST2 and N-acetylgalactosaminyltransferase 1 in the preparation of a medicament for the treatment of bladder cancer.

摘要翻译： 在本发明中提供了异常糖基化的整联蛋白AG-α3和bgr1，以及其作为膀胱癌标记物的用途。 本发明还提供了产生抗AG-α3和bgr1单克隆抗体的杂交瘤细胞，由其分泌的单克隆抗体BCMab1，以及BCMab1在制备用于治疗膀胱癌的药物中的用途。 本发明还提供了GAL3ST2和N-乙酰半乳糖胺基转移酶1的抑制剂在制备用于治疗膀胱癌的药物中的用途。